ProShare Advisors
VTGN icon

ProShare Advisors’s VistaGen Therapeutics VTGN Stock Holding History

ProShare Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-812
Closed -$3.04K – 1910
2023
Q1 		$3.04K Sell
812
-76
-9% -$399 ﹤0.01% 1784
2022
Q4 		$2.74K Buy
888
+173
+24% +$651 ﹤0.01% 1847
2022
Q3 		$3K Sell
715
-14
-2% -$139 ﹤0.01% 1749
2022
Q2 		$20K Sell
729
-484
-40% -$17.1K ﹤0.01% 1767
2022
Q1 		$46K Sell
1,213
-200
-14% -$8.72K ﹤0.01% 2118
2021
Q4 		$82K Buy
1,413
+586
+71% +$38.1K ﹤0.01% 2227
2021
Q3 		$68K Sell
827
-827
-50% -$71.9K ﹤0.01% 1951
2021
Q2 		$156K Buy
+1,654
New +$123K ﹤0.01% 2206

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's VTGN Position: Q2 2023 in Review

ProShare Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 812 shares — an estimated $3.04K sold.

ProShare Advisors first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $156K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • ProShare Advisors reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • ProShare Advisors sold 812 VistaGen Therapeutics shares in Q2 2023, an estimated $3.04K.
  • ProShare Advisors first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
  • ProShare Advisors's VistaGen Therapeutics position peaked at $156K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.